Molecular mechanism of diabetic nephropathy

Clinica Chimica Acta

Volumn 297, Issue 1-2, 2000, Pages 135-144

  Lehmann, Rainer ^a   Schleicher, Erwin D ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cytokines; Diabetic nephropathy; Matrix proteins; Molecular mechanism; Tubular marker proteins

Indexed keywords

COLLAGEN; CYTOKINE; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; TRANSFORMING GROWTH FACTOR BETA1;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME ACTIVITY; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE METABOLISM; HUMAN; KIDNEY DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; HUMANS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034109107     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(00)00240-0     Document Type: Review

References (48)

1. Borch-Johnson K., Andersen P.K., Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 28:1985;590-596.
2. Pettitt D.J., Knowler W.C., Nelson R.G. Familial factors in diabetic nephropathy. Mogensen C.E. The kidney and hypertension in diabetes mellitus. 1997;205-214 Kluwer, Dordrecht.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:1993;977-986.
4. An intensive blood glucose control policy with sulphonylureas or insulin reduces the risk of diabetic complications in patients with type 2 diabetes. Lancet. 352:1998;837-853.
5. Mauer S.M., Ellis E., Bilous R.W., Steffes M.W. The pathology of diabetic nephropathy. Draznin B. Complications of diabetes mellitus. 1989;95-101 Alan R. Liss, New York.
6. Mauer S.M., Steffes M.W., Ellis E.N., Sutherland D.N., Brown D.M., Goetz F.C. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 74:1984;1143-1155.
7. Mogensen C.E., Christensen C.K., Vittinghaus E. The stages in diabetic renal disease. with emphasis on the stage of incipient diabetic nephropathy. Diabetes. 32:1983;64-78.
8. Mogensen C.E. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int. 31:1987;673-689.
9. Osterby R. Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences, and prevention. Diabetologia. 35:1992;803-819.
10. Osterby R., Gall M.A., Schmitz A., Nielsen F.S., Nyberg G., Parving H.-H. Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:1993;1064-1070.
11. Nerlich A., Schleicher E.D., Wiest I., Specks U., Timpl R. Immunohistochemical localization of collagen VI in diabetic glomeruli. Kidney Int. 45:1994;1648-1656.
12. Kim Y., Kleppel M., Butkowski R., Mauer M., Wieslander J., Michael A. Differential expression of basement membrane collagen chains in diabetic nephropathy. Am J Pathol. 138:1991;413-420.
13. Nerlich A., Schleicher E. Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol. 139:1991;889-899.
14. Bohle A., Wermann N., Bogenschütz B., Müller C.A. The pathogenesis of chronic renal failure in diabetic nephropathy. Pathol Res Pract. 187:1991;251-259.
15. Ceol M., Nerlich A., Baggio B., et al. Increased glomerular α1 (IV) collagen expression and deposition in long-term diabetic rats in prevented by chronic glycosaminoglycan treatment. Lab Invest. 74:1996;484-495.
16. Schleicher E., Wagner E.M., Olgemöller B., Nerlich A., Gerbitz K.D. Characterization and localization of basement membrane associated heparan sulfate proteoglycan in human tissues. Lab Invest. 61:1989;323-332.
17. Ayo S.H., Radnik R.A., Glass W.F., et al. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am J Physiol. 260:1990;F185-191.
18. Schleicher E., Nerlich A. The role of hyperglycemia in the development of diabetic complications. Horm Metab Res. 28:1996;367-373.
19. Brownlee M., Cerami A., Vlassara H. Advanced glucosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 318:1988;1315-1321.
20. Mitsuhashi T., Nakayama H., Ithoh T., et al. Immunohistochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. Diabetes. 42:1993;826-832.
21. Witztum J.L., Miyata T., Maeda K., et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest. 100:1997;2995-3004.
22. Schmidt A.M., Yan S.D., Stern D.M. The dark side of glucose. Nat Med. 1:1995;1002-1004.
23. Doi T., Vlassara H., Kirstein M., Yamada Y., Striker G.E., Striker L.J. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Procl Natl Acad Sci USA. 89:1992;2873-2877.
24. Vlassara H., Brownlee M., Cerami A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med. 164:1986;1301-1309.
25. Schmidt A.M., Yan S.D., Wautier J.-L., Stern D. Activation of receptors for advanced glycation end products. A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 84:1999;489-497.
26. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. AGEs and their interaction with AGE receptors in vascular disease and diabetes mellitus. Part I. The AGE concept. Cardiovasc Res. 37:1998;586-600.
27. Yan S., Schmidt A.M., Anderson G.M., et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 269:1994;9889-9897.
28. Bierhaus A., Chevion A., Chevion M., et al. Advanced glycation endproduct (AGEs) induced activation of NFκB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes. 46:1997;1481-1490.
29. Soulis T., Cooper M.E., Sastra S., et al. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia. 40:1997;1141-1151.
30. Kolm-Litty V., Sauer U., Nerlich A., Lehmann R., Schleicher E.D. High glucose-induced transforming growth factor β1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest. 101:1998;160-169.
31. Du X.L., Sui G.Z., Stockklauser-Färber K., et al. Induction of apoptosis by high proinsulin and glucose in cultured human umbilical vein endothelial cells mediated by reactive oxygen species. Diabetologia. 41:1998;249-256.
32. Schleicher E.D. Biochemical aspects of diabetic nephropathy. Mogensen C.E. The kidney in hypertension and diabetes mellitus. 1999;269-279 Kluwer, Dordrecht.
33. Ayo S.H., Radnik R., Garoni J.A., Troyer D.A., Kreisberg J.A. High glucose increases diaclyglycerol mass and activates protein kinase C in mesangial cells. Am J Physiol. 261:1991;F571-577.
34. Larkins R.G., Dunlop M.E. The link between hyperglycaemia and diabetic nephropathy. Diabetologia. 35:1992;499-504.
35. Ishii H., Jirousek M.R., Koya D., et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 272:1996;728-731.
36. Nakamura T., Fukui M., Ebihara I., et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes. 42:1993;450-456.
37. Yamamoto T., Nakamura T., Noble N.A., Ruoslathi E., Border W.A. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA. 90:1993;1814-1818.
38. Iwano M., Kubo A., Nishino T., et al. Quantification of glomerular TGF-β 1 mRNA in patients with diabetes mellitus. Kidney Int. 49:1996;1120-1126.
39. Sharma K., Ziyadeh F.N. Perspectives in diabetes. Hyperglycaemia and diabetic kidney disease. The case for transforming growth factor-β as a key mediator. Diabetes. 44:1995;1139-1146.
40. Kagami S., Border W.A., Miller D.E., Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 93:1994;2431-2437.
41. Diabetic nephropathy. Diabetes Care. 21:1998;S50-53.
42. Hofmann W., Edel H., Guder W.G. Urineiweiß-Differenzierung. Ein neues Konzept zur nichtinvasiven Diagnostik von Nierenerkrankungen. Münch med Wschr. 139:1997;488-494.
43. Ellis D., Forrest K.Y., Erbey J., Orchard T.J. Urinary measurement of transforming growth factor-β and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem. 44:1998;950-956.
44. Sato H., Iwano M., Akai Y., et al. Increased excretion of urinary transforming growth factor beta 1 in patients with diabetic nephropathy. Am J Nephrol. 18:1998;490-494.
45. Mattyus I., Zimmerhackl L.B., Schwarz A., Brandis M., Miltenyi P., Tulassay T. Renal excretion of endothelin in children. Pediatr Nephrol. 11:1997;513-521.
46. Hong C.Y., Chia K.S. Markers of diabetic nephropathy. J Diabet Complic. 12:1998;43-60.
47. Pfohl M., Frost D., Koch M., et al. Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and diabetic nephropathy in IDDM patients. Horm Metab Res. 30:1998;276-280.
48. Mangili R. Microalbuminuria in diabetes. Clin Chem Lab Med. 36:1998;941-946.